



PRESS RELEASE

Alligator Bioscience and SARomics have entered into a collaboration agreement

Lund, September 17, 2007 - Alligator Bioscience, the protein optimization company, is pleased to announce that it has entered into a strategic collaboration agreement with SARomics. Alligator Bioscience intends to offer the services performed at SARomics as an integral part of Alligator Bioscience and wishes to apply SARomics' technology and knowhow in conjunction with its technology platform, in order to decrease the project time for internal and external projects.

About SARomics AB

SARomics specializes in finding and exploring structure-activity-relationships (SAR) in both small molecule-based and protein-based drug discovery projects.

SARomics has since 2005 provided R&D support in the area of *in silico* drug discovery to the pharmaceutical and biotechnology industries as a contract service provider. SARomics has developed a technology platform consisting of both proprietary methods and commercial software for protein modeling, computational chemistry, and quantitative protein sequence-activity modeling activities. SARomics is based in Lund, Sweden, and consists of a highly experienced team with key expertise in drug discovery and design.

For further general information please visit <u>www.saromics.com</u>.

If you have any questions please contact Dr Björn Walse, CEO of SARomics AB, +46 46 191276.

About Alligator Bioscience AB

Alligator Bioscience uses its proprietary FIND® technology to develop new and optimize existing therapeutic and diagnostic proteins.

Since 2001, Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical, diagnostic and biotech industry, improving customers' proteins and helping them to build more competitive pipelines. The company has also created an internal pipeline of therapeutic drug candidates for major clinical indications, which are at varying stages of development.

Alligator Bioscience operates from the Ideon Science Park in Lund, and has 22 employees. The company has around 150 shareholders.

For further general information please visit <u>www.alligatorbioscience.com</u>. If you have any questions please contact Dr Ann-Christin Malmborg Hager, VP Business Development of Alligator Bioscience AB, +46 46 286 4295.